Buyback of Class B shares in Essity during week 12, 2026

Essity completed its buyback program initiated on April 24, 2025, repurchasing a total of 11,566,941 Class B shares for SEK 3bn; 406,220 shares were repurchased between March 16-19, 2026. The repurchases were financed with cash flow from operations after the ordinary dividend. Management signals an ambition to continue recurring share buybacks over time as part of capital allocation.

Analysis

Management’s decision to prioritize recurring buybacks over redeploying cash signals a steady return-of-capital bias rather than an acquisitive growth posture. If sustained, this policy should lift EPS and ROE modestly — think low-to-mid single-digit EPS accretion per year — but only so long as top-line or margin pressure doesn’t erode the base those metrics are measured against.

The immediate beneficiaries are concentrated holders and active managers who can exploit the shrinking free float; index/ETF passive holders will see mechanical weight drift that can amplify short-term price moves on rebalancing days. Competitors with heavier M&A or capex commitments may underperform on headline ROE comparisons, while upstream suppliers (pulp/packaging) face mixed outcomes: less volume growth risk but more pricing leverage pressure if the company squeezes input costs to protect margins.

Key risks are idiosyncratic cash-flow shocks (commodity/pulp inflation, SEK FX moves, or a consumer demand slowdown) that would force a near-term pause and reverse the favorable optics of buybacks. Watch three near-term catalysts: quarterly organic volume trends, net-debt / EBITDA trajectory, and any shifts in capex or dividend policy — each can flip sentiment within one quarter.

Contrarian read: the market may be praising buybacks as durable value-creation while underestimating that they mask stagnant underlying growth; if organic sales slip, buybacks become a band-aid that compresses optionality. Conversely, if management continues to buy at current levels while margins normalize, there’s a multi-quarter asymmetric payoff for patient holders due to compounded share reduction.

Key Decisions for Investors

• Long ESSITY B (STO: ESSITY B) — 6–12 month horizon. Accumulate on any >7% pullback; target +25% total return if buybacks persist and margins stabilize. Set tactical stop-loss at -10% from entry to limit drawdowns if organic trends deteriorate.
• Pair trade: Long ESSITY B (STO: ESSITY B) / Short KMB (NYSE:KMB) — 3–9 months. Expect ESSITY to outperform as buybacks compound EPS while KMB’s slower capital return or higher growth multiple re-rates lower; target pair outperformance of 10–15%, max pair loss 8–12%.
• Buy 12-month calls to add convexity — purchase ESSITY B LEAP-style calls (~25% OTM) sized to risk no more than 1.5% of book. Rationale: asymmetric upside if buybacks continue and margins recover; defined premium loss if cash flow shock hits.
• Hedge: If worried about commodity-driven reversal, buy short-dated puts on pulp/commodity proxies or add a SEK-weakness hedge (FX forwards) for a 3–6 month bridge to earnings prints that validate cash-flow stability.